Melanotan 2 UK: Melanocortin Receptor Mechanisms and Research Applications

Dorr RT et al. (1996) documented the first controlled human trials of melanotan-II administration, reporting dose-dependent melanogenesis at subcutaneous doses ranging from 0.025 mg/kg to 0.25 mg/kg in healthy volunteers (PMID: 8801281). What distinguishes MT-2 from endogenous α-MSH is its resistance to enzymatic degradation and its non-selective affinity for melanocortin receptor subtypes—specifically MC1R (epidermal melanocytes) and MC4R (hypothalamic and spinal erectile centres). These are functionally independent pathways, yet UK-based content on melanotan 2 routinely conflates pigmentation and sexual effects as if mediated by a single mechanism. This article clarifies the molecular pharmacology, reviews published human data, and addresses sourcing considerations for researchers procuring Melanotan 2 10mg UK supplies.

Melanocortin Receptor Subtypes: Why MT-2 Produces Multiple Phenotypes

Melanotan-II is a cyclic heptapeptide analog of α-melanocyte stimulating hormone (α-MSH), modified at positions 4 and 10 to form a lactam bridge that confers proteolytic stability and receptor promiscuity. Unlike α-MSH, which shows preferential MC1R affinity, MT-2 binds with nanomolar affinity to MC1R, MC3R, MC4R, and MC5R. The dual phenotypic effects—cutaneous pigmentation and erectile function—arise from activation of spatially and functionally discrete receptor populations.

MC1R Activation: Epidermal Melanogenesis

MC1R is expressed on epidermal and follicular melanocytes throughout the integument. Upon binding MT-2, MC1R couples to adenylyl cyclase via Gαs, elevating intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates cAMP response element-binding protein (CREB), which upregulates microphthalmia-associated transcription factor (MITF). MITF is the master regulator of melanogenic enzymes: tyrosinase, tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (DCT). Tyrosinase catalyzes the rate-limiting hydroxylation of L-tyrosine to L-DOPA and subsequent oxidation to dopaquinone, the precursor to eumelanin and pheomelanin polymers.

This cascade produces constitutive melanin synthesis independent of ultraviolet exposure. Dorr et al. (1996) observed visible tanning at 0.16 mg/kg cumulative dose over 10 days, with pigmentation persisting 30–60 days post-administration in study participants (PMID: 8801281). Importantly, MC1R activation does not require concurrent UV radiation, though UV exposure accelerates pigment oxidation and distribution within keratinocytes.

MC4R Activation: Centrally Mediated Erectile Response

MC4R is predominantly expressed in hypothalamic paraventricular nucleus (PVN) neurons and within the sacral spinal cord autonomic nuclei. Wessells H et al. (1998) demonstrated that MT-2 administration (0.025 mg/kg subcutaneous) in men with organic erectile dysfunction produced spontaneous erections in 8 of 10 subjects within 2 hours, independent of visual or tactile stimulation (PMID: 9869628). This effect is mediated by MC4R activation in PVN oxytocin-releasing neurons, which project to sacral preganglionic neurons innervating the cavernous nerve. Oxytocin release triggers nitric oxide synthase (NOS) activity in endothelial cells lining the corpora cavernosa, producing NO-mediated smooth muscle relaxation and penile tumescence.

King SH et al. (2007) reviewed the melanocortin-erectile pathway and noted that MC4R knockout mice exhibit complete abolition of MT-2-induced erections, confirming receptor specificity (PMID: 17185243). Critically, this pathway is anatomically and pharmacologically distinct from MC1R-mediated pigmentation: PVN neurons lack melanin-producing machinery, and melanocytes lack the oxytocinergic projections required for erectile signaling.

Understanding this receptor dichotomy is essential when interpreting published dose-response data and when UK researchers design protocols involving Melanotan 2 10mg UK vials. A dose sufficient for pigmentation (MC1R) may be sub-threshold for erectile effects (MC4R), or vice versa, depending on individual receptor expression and baseline hormonal status.

What the Clinical Literature Demonstrates

Phase I Data: Safety and Dose-Response (Dorr et al., 1996)

Dorr RT et al. (1996) conducted an open-label dose-escalation trial in 10 healthy male volunteers. Subjects received subcutaneous MT-2 at 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.16 mg/kg, and 0.25 mg/kg over successive administration days. Primary endpoints were adverse event incidence and pigmentation intensity (via reflectance spectrophotometry). Key findings included:

• Pigmentation onset: Visible tanning appeared at cumulative doses ≥0.16 mg/kg, with 2–4 Fitzpatrick skin type unit darkening relative to baseline.
• Duration: Pigmentation persisted 4–8 weeks post-cessation without UV maintenance exposure.
• Adverse effects: Nausea (80% of subjects at ≥0.1 mg/kg), facial flushing (60%), and spontaneous erections (70% at ≥0.16 mg/kg). Nausea was dose-dependent and transient, resolving within 2 hours.
• Pharmacokinetics: Subcutaneous absorption half-life ~30 minutes; elimination half-life ~2 hours. Plasma concentrations peaked at 1 hour post-injection.

No serious adverse events, hepatotoxicity, or nephrotoxicity were recorded at any dose level. These findings established a preliminary therapeutic window and informed subsequent erectile dysfunction trials.

Erectile Dysfunction Trial (Wessells et al., 1998)

Wessells H et al. (1998) enrolled 10 men with documented organic ED (mean age 49 years, range 35–62) in a double-blind, placebo-controlled crossover trial. Subjects self-administered 0.025 mg/kg MT-2 or saline subcutaneously in a clinic setting. Erectile response was assessed using RigiScan monitoring and patient-reported outcomes. Results included:

• Erectile response rate: 80% of subjects achieved erections sufficient for penetration (≥60% rigidity) within 2 hours of MT-2 administration, compared to 10% on placebo (p < 0.01).
• Duration: Erections persisted 2–6 hours, with detumescence occurring gradually without intervention.
• Adverse effects: Nausea (70%), yawning/stretching (50%), and mild facial flushing (40%). No priapism or cardiovascular events occurred.
• Non-responders: Two subjects failed to respond to MT-2; both had severe corporal fibrosis from prior radical prostatectomy, suggesting that intact cavernous nerve pathways are necessary for MC4R-mediated erectile signaling.

This trial established proof-of-concept for centrally acting erectogenic peptides and directly informed the development of PT-141 10mg UK, a selective MC4R agonist lacking MC1R affinity (and thus pigmentation side effects).

Mechanistic Review (King et al., 2007)

King SH et al. (2007) synthesized preclinical and clinical data on melanocortin receptor pathways in sexual function. The authors highlighted that MT-2’s erectogenic effects are preserved in men with peripheral vascular insufficiency and diabetes—conditions that attenuate phosphodiesterase-5 inhibitor efficacy (PMID: 17185243). This suggests that MC4R agonism bypasses the NO-cGMP pathway’s rate-limiting steps, instead amplifying upstream oxytocin-mediated NOS activation. The review also noted that female sexual arousal responses to MT-2 were documented in pilot trials, indicating cross-sex generalizability of MC4R-mediated libido enhancement, though published data remain limited.

UK Sourcing and Purity Verification Standards

Melanotan-II is not a licensed medicinal product in the United Kingdom and is not approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for human therapeutic use. It is legally supplied for research purposes only under UK law. Researchers procuring MT-2 must verify analytical purity and identity to ensure experimental validity and participant safety.

Why ≥99% HPLC-Verified Purity Matters

High-performance liquid chromatography (HPLC) with UV detection at 214 nm (peptide bond absorbance) or 280 nm (aromatic residue absorbance) is the gold standard for peptide purity quantification. A ≥99% purity specification indicates that ≥99% of the lyophilized mass consists of the target peptide sequence, with <1% impurities including:

• Truncated sequences: Deletion peptides missing N- or C-terminal residues due to incomplete solid-phase synthesis coupling.
• Deamidation products: Asparagine or glutamine residues converted to aspartic or glutamic acid via non-enzymatic hydrolysis.
• Oxidation products: Methionine residues oxidized to methionine sulfoxide.
• Trifluoroacetic acid (TFA): Residual cleavage reagent from peptide synthesis, present as a counter-ion to basic residues.

Impurities alter pharmacokinetics, receptor affinity, and immunogenicity. For example, deamidated MT-2 exhibits 10-fold reduced MC4R affinity, potentially explaining inter-batch variability in erectile response rates reported anecdotally in non-peer-reviewed forums. TFA content >5% (w/w) causes injection site irritation and may interfere with lyophilization stability.

Arma Peptides supplies Melanotan 2 10mg UK with published Certificates of Analysis (COAs) for each manufactured batch. COAs include HPLC chromatograms, mass spectrometry confirmation of molecular weight (1024.2 Da for acetate salt), and endotoxin testing (LAL assay, ≤1 EU/mg). UK-based researchers should request COAs prior to procurement and verify that lot numbers on vial labels match COA documentation.

Reconstitution and Storage

MT-2 is supplied as a lyophilized powder in sterile 10 mg vials. Reconstitution is performed using bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection (WFI). Bacteriostatic water extends multi-dose vial stability to 28 days at 2–8°C, whereas WFI-reconstituted peptide should be used within 72 hours or discarded. Reconstituted MT-2 should not be frozen, as freeze-thaw cycles induce aggregation and loss of bioactivity.

Lyophilized MT-2 is stable for 24 months at -20°C and 6 months at 2–8°C when protected from light and moisture. Researchers should store unopened vials in light-protective packaging and desiccated containers to prevent humidity-induced degradation.

Research Protocols from Published Literature

The following protocols are derived from published human trials and are presented for reference purposes only. They do not constitute medical advice, prescribing information, or endorsement of off-label use. All MT-2 research conducted in the UK must comply with Human Tissue Authority (HTA) regulations and obtain appropriate ethical approval from a Research Ethics Committee (REC).

Pigmentation Study Protocol (Dorr et al., 1996)

Subjects received subcutaneous injections in the abdominal fold using 0.5 mL insulin syringes (29-gauge needle). Dosing commenced at 0.025 mg/kg and escalated by 100% increments every 48 hours until target cumulative dose (0.16–0.25 mg/kg) was achieved. Pigmentation was assessed via tristimulus reflectance colorimetry (L*a*b* color space) at baseline, 7 days, 14 days, and 30 days post-final dose. Nausea prophylaxis was not administered; subjects were instructed to remain seated for 30 minutes post-injection and avoid food intake 2 hours pre- and post-administration to minimize gastrointestinal side effects.

Erectile Function Protocol (Wessells et al., 1998)

Subjects self-administered 0.025 mg/kg MT-2 subcutaneously 2 hours prior to anticipated sexual activity. RigiScan monitoring was initiated immediately post-injection and continued for 6 hours. Subjects were instructed to avoid phosphodiesterase inhibitors, nitrates, and alpha-blockers for 48 hours pre-study. Sexual stimulation was not provided during the monitoring period; erections were spontaneous. Crossover washout period was 7 days to ensure complete peptide elimination.

Loading and Maintenance Dosing (Non-Published Observational Data)

Though not formally published in peer-reviewed literature, observational research protocols frequently employ a “loading phase” of 0.5–1.0 mg daily for 7–10 days, followed by a “maintenance phase” of 0.5–1.0 mg 2–3 times weekly. This approach is hypothesized to saturate melanocortin receptors during the initial phase and sustain receptor occupancy during maintenance. However, no controlled trials have validated this regimen’s efficacy or safety relative to the published Dorr and Wessells protocols.

UK researchers designing novel protocols should reference the published dose ranges (0.025–0.25 mg/kg) and consider inter-individual variability in body mass, receptor polymorphisms (e.g., MC1R variants conferring red hair/fair skin phenotype), and concurrent medication use (e.g., CYP3A4 inhibitors that may alter peptide metabolism).

Comparison with Related Melanocortin Agonists

Researchers requiring isolated erectile effects without pigmentation should consider PT-141 10mg UK, which retains MC4R agonism but lacks MC1R affinity due to structural modifications at positions 6 and 7. Conversely, subjects seeking photoprotective pigmentation without sexual side effects have no selective MC1R agonist available commercially; α-MSH is enzymatically unstable and unsuitable for exogenous administration.

Frequently Asked Questions

1. What is the difference between Melanotan-I and Melanotan-II?

Melanotan-I (afamelanotide, marketed as Scenesse®) is a linear 13-amino acid peptide with selective MC1R affinity. It produces potent pigmentation with minimal erectile or appetite effects, and is approved in the EU for erythropoietic protoporphyria photoprotection. Melanotan-II is a shorter 7-amino acid cyclic peptide with non-selective melanocortin receptor binding, producing pigmentation, erectile enhancement, and appetite suppression. MT-2’s cyclization (lactam bridge between Asp-Phe residues) confers proteolytic resistance and MC4R affinity absent in MT-I. In the UK, neither is licensed for cosmetic tanning; MT-I is available only via specialist dermatology prescription, whereas MT-II is supplied for research use.

2. Does Melanotan-II require UV exposure to produce tanning?

No. MT-2 stimulates constitutive melanogenesis via MC1R-cAMP-MITF signaling independent of UV radiation. However, UV exposure accelerates melanin oxidation (conversion of colorless leucomelanin to brown/black eumelanin) and enhances melanin transfer from melanocytes to keratinocytes, producing more visible pigmentation. Subjects using MT-2 without UV exposure will develop tan coloration, though onset may be slower (10–14 days versus 5–7 days with concurrent UV). Importantly, MT-2-induced pigmentation does not confer proportional photoprotection; melanin produced via α-MSH pathways is less uniformly distributed and offers lower UV absorption than naturally UV-induced pigmentation. Researchers should not assume that MT-2 provides sunburn protection equivalent to a natural tan of similar visual intensity.

3. Why does MT-2 cause nausea, and how can it be mitigated?

Nausea results from MC4R activation in the area postrema (brainstem chemoreceptor trigger zone) and hypothalamic appetite-regulating nuclei. MC4R agonism reduces ghrelin signaling and activates proopiomelanocortin (POMC) neurons, producing anorexigenic effects and gastric motility suppression. Dorr et al. (1996) reported nausea in 80% of subjects at doses ≥0.1 mg/kg, with symptom onset 20–40 minutes post-injection and resolution within 2 hours. Mitigation strategies include:

• Dose escalation: Commencing at 0.25 mg (well below 0.025 mg/kg for a 70 kg individual) and increasing by 0.25 mg increments every 2–3 days allows MC4R desensitization and reduces nausea incidence.
• Evening administration: Dosing 30 minutes before sleep permits subjects to sleep through peak nausea window.
• Antiemetic pretreatment: Ondansetron (5-HT3 antagonist) or metoclopramide (D2 antagonist) administered 30 minutes pre-MT-2 reduces nausea severity, though no controlled trials have validated this approach.
• Fasting state: Avoiding food 2 hours pre- and post-injection reduces gastric distension and nausea intensity.

Nausea typically resolves after 7–10 days of consistent dosing due to MC4R receptor downregulation in the area postrema. Subjects experiencing persistent vomiting (>3 episodes) should discontinue use and consult study oversight personnel.

4. What is the legal status of Melanotan-II in the UK?

MT-2 is not a licensed medicine under the Human Medicines Regulations 2012 and is not approved by the MHRA for human therapeutic or cosmetic use. It is not a controlled substance under the Misuse of Drugs Act 1971, meaning possession for personal use is not a criminal offense. However, supplying MT-2 for human administration (cosmetic tanning or sexual enhancement) violates UK medicines legislation, as unlicensed medicinal products may only be supplied under a Special License or for research purposes.

Arma Peptides supplies MT-2 exclusively for in vitro research and academic/non-clinical laboratory use. Researchers must hold appropriate institutional ethical approval (from an NHS Research Ethics Committee or university ethics board) to administer MT-2 in human studies. Purchase and possession by individuals without research credentials or ethical oversight is undertaken at the individual’s legal risk.

Importantly, the UK’s National Health Service (NHS) and the Cosmetic, Toiletry and Perfumery Association (CTPA) have issued public health warnings regarding “illegal tanning injections,” citing case reports of contamination, incorrect dosing, and adverse reactions from unregulated suppliers. Researchers should procure only from suppliers providing batch-specific COAs and HPLC verification, such as those available via the Shop section at Arma Peptides.

5. How long does Melanotan-II-induced pigmentation persist after discontinuation?

Dorr et al. (1996) documented pigmentation persistence of 30–60 days post-cessation in subjects receiving cumulative doses of 0.16–0.25 mg/kg. Melanin degradation follows keratinocyte turnover kinetics: epidermal keratinocytes migrate from the basal layer to the stratum corneum over 28–40 days, after which they desquamate. Since MT-2 stimulates melanin synthesis in basal melanocytes, newly produced melanin is incorporated into keratinocytes that require 4–6 weeks to reach the skin surface and shed. Consequently, pigmentation fades gradually rather than abruptly, with half-maximal color intensity at approximately 3–4 weeks post-final dose.

Maintenance dosing (e.g., 0.5 mg twice weekly) sustains pigmentation indefinitely by continuously stimulating basal melanocyte melanogenesis, replacing melanin lost via keratinocyte turnover. No published data quantify the minimum maintenance dose required to sustain steady-state pigmentation, though observational protocols suggest 1–2 mg/week is sufficient for most individuals.

Quality Assurance and UK Delivery

Arma Peptides manufactures and supplies research-grade melanotan-II with ≥99% purity verified by third-party HPLC analysis. Each 10 mg vial includes a tamper-evident seal, sterile lyophilization, and light-protective packaging. Batch-specific Certificates of Analysis are published online and include:

• HPLC chromatogram with retention time and peak purity percentage
• Mass spectrometry (ESI-MS) confirming molecular weight (1024.2 Da)
• Peptide content quantification (mg per vial, adjusted for acetate and TFA counter-ion mass)
• Endotoxin testing (LAL assay, specification ≤1 EU/mg)
• Appearance (white to off-white lyophilized powder)

UK delivery is fulfilled via next-day courier with cold-chain packaging (gel ice packs, insulated liners) to maintain 2–8°C during transit. Orders exceeding £150 qualify for free UK shipping. International delivery to EU and non-EU countries is available for academic institutions with research import permits. All shipments include a declaration of “research peptides for laboratory use” to comply with UK customs regulations.

Researchers requiring additional peptides for comparative studies—such as PT-141 10mg UK (selective MC4R agonist) or other melanocortin analogs—can browse the full catalog at the Home page or directly via the Shop.

Conclusion

Melanotan-II represents a pharmacologically distinct class of melanocortin receptor agonist, producing dose-dependent pigmentation via MC1R and erectile enhancement via MC4R through spatially and mechanistically separate pathways. Published human trials (Dorr et al., 1996; Wessells et al., 1998) establish a preliminary safety profile and dose-response relationship, though long-term safety data and large-scale efficacy trials remain absent from peer-reviewed literature. UK researchers designing protocols involving MT-2 must ensure analytical purity verification (≥99% HPLC), ethical approval, and participant informed consent regarding the peptide’s unlicensed regulatory status.

Arma Peptides supplies research-grade Melanotan 2 10mg UK with published COAs, cold-chain UK delivery, and technical support for protocol design. All products are intended exclusively for non-clinical research and are not for human therapeutic or cosmetic use.

Disclaimer

This article is provided for educational and informational purposes only. Melanotan-II is not approved by the MHRA or EMA for human use and is supplied by Arma Peptides solely for in vitro research and laboratory applications. The content herein does not constitute medical advice, clinical guidance, or endorsement of off-label use. Researchers must obtain appropriate ethical approval and regulatory authorization prior to administering MT-2 in human studies. Arma Peptides assumes no liability for misuse, adverse events, or legal consequences arising from improper handling or administration. UK law prohibits the supply of unlicensed medicines for human therapeutic use outside of approved clinical trials. Always consult institutional review boards, research ethics committees, and qualified medical professionals before commencing peptide research involving human participants.